Core Insights - The approval of VELSIPITY (Arginine Eculizumab Tablets) by the NMPA marks a significant advancement in the treatment of moderate to severe active ulcerative colitis (UC) in adults, addressing a critical gap in the market for patients unresponsive to traditional therapies [1][2][4] Group 1: Product Overview - VELSIPITY is a next-generation high-selectivity S1P receptor modulator, designed for once-daily oral administration, offering rapid onset and effective deep mucosal healing, with a strong safety profile [1][3] - The drug is projected to reach peak sales of 5 billion RMB, positioning it as a core product for the company following its success with renal disease treatment [1][6] Group 2: Market Context - The incidence of ulcerative colitis in China is rising, with an expected increase in patient numbers from approximately 980,000 in 2025 to about 1.5 million by 2031, highlighting the urgent need for effective treatments [2] - Current treatment options are limited, with existing therapies facing challenges such as limited efficacy, high relapse rates, and adverse reactions [2][5] Group 3: Clinical Efficacy - Clinical trials have demonstrated VELSIPITY's significant efficacy, with a clinical remission rate of 48.1% and a mucosal healing rate of 51.9% over 40 weeks of maintenance treatment [3][4] - The drug has been recognized in multiple international guidelines as a first-line treatment for ulcerative colitis, underscoring its clinical value [4] Group 4: Commercialization Strategy - The company has established a comprehensive A2MS operational system to facilitate the market entry of VELSIPITY, leveraging its scientific and commercial insights [5][6] - VELSIPITY is set to be included in the urgent import drug directory for clinical use in the Greater Bay Area in 2024, providing a first-mover advantage [6][7] Group 5: Financial Outlook - The approval of VELSIPITY enhances the company's revenue structure, with expectations of significant growth in revenue and profitability as it expands its product portfolio [6][7] - The company aims to achieve over 15 billion RMB in revenue by 2030, driven by a combination of existing and new product sales, with a projected compound annual growth rate exceeding 50% from 2025 to 2030 [7]

Core Viewpoint - Yunding Xinyao's core product VELSIPITY has received approval from the NMPA for treating moderate to severe active ulcerative colitis (UC) in adults, filling a significant gap in treatment options and is expected to generate peak sales of 5 billion RMB [1][6]. Group 1: Product Approval and Market Potential - VELSIPITY is a new generation S1P receptor modulator that offers rapid onset and effective mucosal healing, providing a new first-line treatment option for UC patients [1][3]. - The approval of VELSIPITY is anticipated to drive significant growth for Yunding Xinyao, marking a major breakthrough in the autoimmune disease sector [6][7]. - The drug's peak sales potential is projected to reach 5 billion RMB, contributing to the company's revenue growth alongside existing products [6][7]. Group 2: Clinical Efficacy and Guidelines - Clinical studies have shown VELSIPITY's efficacy, with a clinical remission rate of 48.1% and a mucosal healing rate of 51.9% after 40 weeks of treatment [3][4]. - VELSIPITY has been included in major international clinical guidelines as a first-line treatment for UC, reflecting its recognized clinical value [4][5]. Group 3: Commercialization Strategy - Yunding Xinyao has established a comprehensive A2MS operational system to efficiently promote VELSIPITY's market entry and clinical application [5][6]. - The company aims to accelerate the commercialization process and integrate VELSIPITY into the national medical insurance directory to enhance accessibility for patients [1][6]. Group 4: Future Growth and Strategic Goals - Yunding Xinyao's 2030 strategic goal includes achieving over 15 billion RMB in revenue and expanding its product portfolio to over 20 commercialized products [6][7]. - The company expects a compound annual growth rate of over 50% from 2025 to 2030, with a focus on both BD collaborations and independent research and development [7].

Core Viewpoint - The approval of VELSIPITY for the treatment of moderate to severe active ulcerative colitis (UC) in adults marks a significant milestone for the company and aligns with its 2030 development strategy [1] Group 1: Company Developments - The company’s stock rose over 5% in the afternoon trading session, currently up 3.4% at HKD 40.18, with a trading volume of HKD 151 million [1] - The National Medical Products Administration (NMPA) of China has approved the new drug application for VELSIPITY, which is intended for patients who have inadequate response, loss of response, or intolerance to traditional therapies or biological agents [1] - The company plans to actively prepare for the commercialization of VELSIPITY and aims to expedite the availability of this therapy to domestic patients while pushing for its inclusion in the national medical insurance catalog [1] Group 2: Strategic Goals - The approval of VELSIPITY is a crucial part of the company's 2030 development strategy, which emphasizes a dual approach of "BD collaboration + self-research" to create certain value through commercialization and growth value through research and development [1] - The company aims to strengthen its core therapeutic area advantages, advance innovative drug research and commercialization, and establish a sustainable growth model as a global innovative biopharmaceutical enterprise [1]

Core Insights - The approval of Velsipity (Arginine Acumod Tablets) by the NMPA marks a significant milestone for the company in establishing its leading position in the autoimmune field [1][3] - Velsipity is a new generation high-selectivity S1P receptor modulator that offers a new first-line treatment option for adult patients with moderate to severe active ulcerative colitis [2] - The company aims to commercialize Velsipity quickly and push for its inclusion in the national medical insurance directory as part of its 2030 development strategy [3] Clinical Research - The approval is based on results from the ENLIGHT UC study, the largest Phase III registration clinical trial for moderate to severe active ulcerative colitis patients in Asia, involving 340 patients [2] - Velsipity demonstrated statistical significance and clinical relevance in all primary and secondary efficacy endpoints during the 12-week induction and 40-week maintenance treatment periods [2] - The ELEVATE UC Phase III studies further validated Velsipity's favorable benefit-risk profile [2] Commercialization Strategy - The company has laid out plans to establish a comprehensive commercialization system and aims to achieve revenue exceeding 10 billion RMB by 2028 and over 15 billion RMB by 2030 [4] - The revenue growth rate is projected to exceed 50% from 2025 to 2030, with a target of maintaining over 15% growth post-2030 [4] - The number of commercialized products is expected to increase to over 20, including Velsipity and other key products [4] Future Development Plans - The 2030 development strategy signifies a crucial milestone for the company in advancing towards the forefront of global biopharmaceuticals [5] - The company plans to introduce 3 to 5 late-stage blockbuster products annually and aims to contribute 6 billion RMB in revenue from over 20 high-value assets by 2030 [5] - The strategic focus will be on maintaining leadership in core therapeutic areas and innovative drug development, aiming to become a leading comprehensive biopharmaceutical company globally [5]